Periplocymarin Induced Colorectal Cancer Cells Apoptosis Via Impairing PI3K/AKT Pathway

Yi Cheng¹, Guiying Wang²,³*, Lianmei Zhao⁴*, Suli Dai⁴, Jing Han⁵, Xuhua Hu², Chaoxi Zhou⁵, Feifei Wang², Hongqing Ma², Baokun Li² and Zesong Meng²

¹ Department of Dermatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, ² Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, ³ Department of Gastrointestinal Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, China, ⁴ Scientific Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, ⁵ Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Colorectal cancer (CRC) is one of the most common cancers worldwide, and approximately one-third of CRC patients present with metastatic disease. Periplocymarin (PPM), a cardiac glycoside isolated from Periploca sepium, is a latent anticancer compound. The purpose of this study was to explore the effect of PPM on CRC cells. CRC cells were treated with PPM and cell viability was evaluated by CCK-8 assay. Flow cytometry and TUNEL staining were performed to assess cell cycle and apoptosis. Quantitative proteomics has been used to check the proteins differentially expressed by using tandem mass tag (TMT) labeling and liquid chromatography–tandem mass spectrometry. Bioinformatic analysis was undertaken to identify the biological processes that these differentially expressed proteins are involved in. Gene expression was analyzed by western blotting. The effect of PPM in vivo was primarily checked in a subcutaneous xenograft mouse model of CRC, and the gene expression of tumor was checked by histochemistry staining. PPM could inhibit the proliferation of CRC cells in a dose-dependent manner, induce cell apoptosis and promote G0/G1 cell cycle arrest. A total of 539 proteins were identified differentially expressed following PPM treatment, where among those there were 286 genes upregulated and 293 downregulated. PPM treatment caused a pro-apoptosis gene expression profile both in vivo and in vitro, and impaired PI3K/AKT signaling pathway might be involved. In addition, PPM treatment caused less detrimental effects on blood cell, hepatic and renal function in mice, and the anti-cancer effect was found exaggerated by PPM+5-FU combination treatment. PPM may perform anti-CRC effects by promoting cell apoptosis and this might be achieved by targeting PI3K/AKT pathway. PPM might be a safe and promising anti-cancer drug that needs to be further studied.

Keywords: colorectal cancer, periplocymarin, apoptosis, IRS1, PI3K/AKT pathway
INTRODUCTION

Global cancer statistics for 2020 showed that colorectal cancer (CRC) ranks third in terms of cancer incidence, but second in terms of cancer mortality, where more than 1.9 million new CRC cases and 935,000 deaths were estimated to occur worldwide (1). In developed countries, five-year survival of patients with CRC has been improved due to early screening, however, up to 25% patients still present with stage 4 disease, while 25 to 50% present with early-stage disease and subsequently go on to develop metastatic disease (2, 3). The prognosis for patients with metastatic CRC remains poor, with a median five-year survival of CRC in 2012–2015 just 56.9% in China (4). Chemotherapeutic agents such as FOLFOX, the main therapy strategy for CRC patients, are effective but combined with unwanted toxicity and side effects (5). Therefore alternative treatment options are urgently required.

To date, about 85% of all approved small-molecule anticancer drugs are from natural products directly or indirectly (6). Periploccymarin (PPM) is isolated from cortex periplocae, the dry root of Periploca sepium Bge, which is traditionally used as an antirheumatic and diuretic agent in Chinese medicine (7). Previous studies have indicated that, PPM performed anti-tumor effects in various of cancer (8, 9). For example, it has been found that PPM promoted prostate adenocarcinoma (PC3) cell apoptosis and inhibit proliferation of U937, HCT-8, Bel-7402, BGC823, A549, and A2780 cell lines in vitro with IC50 values of 0.02–0.29 mM (10). Recently, PPM has been shown to exhibit the advantages of quick effect, short duration, and no accumulation (11). Furthermore, PPM is highly permeable with absence of P-glycoprotein efflux and cytochrome P450, indicating it is a potential natural compound for drug development (12). However, the effect of PPM on CRC has been seldom performed. In the present study, we have investigated the effect of PPM on CRC, to provide more candidate drugs for CRC patients and prolong their lives.

MATERIALS AND METHODS

Cell Culture

The CRC cell lines HCT 116, SW480, RKO, and HT-29 were purchased from Type Culture Collection of the Chinese Academy of Science (Shanghai, China) (catalogue numbers were TCHu 99, TCHu172, TCHu116, and TCHu103, respectively) and preserved by the Scientific Research Center of the Fourth Hospital of Hebei Medical University. All cells were cultured in DMEM (Gibco Invitrogen, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco Invitrogen, Grand Island, NY, USA), penicillin (100 U/ml), and streptomycin (100 µg/ml) (Invitrogen, Carlsbad, California, USA) and incubated at 37°C in air containing 5% CO2.

CCK-8 Assay

PPM (purity ≥98%) was obtained from Tauto Biotechnology Co., Ltd (catalogue number E-2462, Shanghai, China). PPM was dissolved in DMSO and diluted to 12.5, 25, 50, or 100 ng/ml using DMEM medium (final concentration of DMSO <0.01%). Cells (1 x 10^4 cells/well) were exposed to different concentrations of PPM (12.5, 25, 50, or 100 ng/ml) for 24 and 48 h separately. Cells with 0.01% DMSO but no PPM treatment were set as DMSO group. Cells without either PPM or DMSO treatment were set as control. Cell Counting Kit 8 (CCK-8) assay was performed to detect the proliferative ability of CRC cell lines according to the manufacturer’s instructions. Briefly, 10 µl of CCK-8 solution (Meilun Biotechnology, Dalian, China) was added to each well by incubation for 2 h at 37°C in the dark. The absorbance was measured at 450 nm using spectrophotometer. The proliferation rate was calculated by the formula: proliferation rate = (As – Ac)/ (Ac – Ab), in which As represents the test group, Ac the negative control group, and Ab the blank control group.

According to the results, HCT 116 and RKO cells treated with PPM (12.5, 25, 50, or 100 ng/ml) for 24 h were used for apoptosis and cell cycle analysis.

Cell Apoptosis Detection

Cellular apoptosis was quantified by both flow cytometry and TUNEL staining kit. Briefly, approximately 5 x 10^5 cells were harvested and suspended in 500 µl of binding buffer containing Annexin V and propidium iodide (PI) (both 5 µl) (BD Biosciences, San Diego, CA, USA). Then cells were incubated and analyzed by Annexin V-FITC/PI Staining kit according to the manufacturer’s instruction.

TUNEL staining was performed by using kit (Roche Diagnostic GmbH, Penzberg, Germany) following the manufacturer’s protocol. Cells were fixed by 4% paraformaldehyde and washed twice with PBS, and then incubated in solution containing 10 µl of 0.1% Triton X-100 (Sigma-Aldrich, USA) and 10 ml of 0.1% sodium citrate for 2 min. After drying, the TUNEL staining reaction solution was added to the cells, which was followed by 60 min incubation at 37°C in the dark. The cells were observed under a fluorescence microscope. Cells with 0.01% DMSO but no PPM treatment were set as control group.

Cell Cycles Detection

Cell cycles were also determined by flow cytometry. Approximately 1 x 10^6 cells were harvested and suspended with 1 ml of DNA staining solution and 10 µl of permeabilization solution (MultiSciences Biotech, Hangzhou, China). Cells were incubated at room temperature in the dark for 30 min and then analyzed.

Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis

Proteins were extracted from HCT 116 cells treated by 50 ng/ml PPM for 24 h and untreated cells respectively by SDS [4% (w/v) SDS, 100 Mm Tris/HCl pH 7.6, 0.1 MDTT] lysis and quantified using a BCA Protein Assay Kit (Bio-Rad, Hercules, CA, USA). The proteins were digested using filter-aided sample preparation (FASP) and the peptide fraction was quantified. Peptides from each sample (100 µg) were labeled with TMTs (Thermo Fisher Scientific) according to the manufacturer’s instructions.
The tryptic peptides were fractionated using a high-pH reverse-phase high-performance liquid chromatography (HPLC) system using a Thermo Betasil C18 column (10 cm, ID75 µm, 3 µm, C18-A2). Briefly, one unit of TMT reagent was thawed and reconstituted in acetonitrile. The peptide mixtures were then incubated for 2 h at room temperature and pooled, desalted, and dried by vacuum centrifugation. HPLC-MS/MS was performed using an Easy nLC system (Thermo Fisher Scientific) coupled to Q Exactive mass spectrometer (Thermo Fisher Scientific).

Bioinformatic Analysis
The gene ontology (GO) annotation of differentially expressed proteins (DEPs) was performed by Blast2GO software (http://blast2go.com). Functional annotation was based on the online Kyoto Encyclopedia of Genes and Genomes (KEGG) Automatic Annotation Server database (http://www.kegg.jp/). A fold-change < 0.83 or > 1.2 with a P-value (Student’s t-test) < 0.05 was selected as the cutoff criteria for the identification of DEPs. GO enrichment and KEGG pathway enrichment was performed based on the Fisher’s exact test with a PDR value < 0.01.

Western Blot Analysis
Total protein was extracted using RIPA lysis buffer containing protease inhibitors (APEX BIO Technology, Houston, USA). Protein concentrations were determined using BCA Protein Assay Kit (Bio-Rad, Hercules, CA, USA). Then 10% SDS-PAGE gel electrophoresis was carried out using 50 µg of protein from each sample. After gel transfer, PVDF membranes were incubated with primary antibodies including rabbit anti-Bax (1:1,000, Proteintech, Wuhan, China), Bcl-2 (1:1,000, Proteintech, Wuhan, China), survivin (1:1,000, Proteintech, Wuhan, China), cleaved caspase-3 (1:1,000, Proteintech, Wuhan, China), cleaved caspase-9 (1:1,000, Proteintech, Wuhan, China), p21 (1:1,000, Proteintech, Wuhan, China), cyclin D1 (1:1,000, Proteintech, Wuhan, China), IRS1 (1:1,000, Affinity, USA), p-PI3K (1:1,000, Affinity, USA), PI3K (1:1,000, Affinity, USA), and p-AKT (1:200, Affinity, USA) overnight at 4°C. The membranes were washed, membranes were further incubated with fluorochrome-labeled anti-rabbit IgG secondary antibody (1:10,000, Proteintech, Wuhan, China) for 1 h at room temperature. The membranes were imaged using the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA), which was used to normalize relative expression level of each protein to GAPDH.

Animal Experiments
The animal studies were conducted in accordance with the international standards-3R principle of animal welfare, and approved by the Experimental Animal Ethics Committee of the Fourth Hospital of Hebei Medical University. Approximately 5–6 weeks old Male BALB/c nude mice were obtained from the Beijing Vital River Laboratory Animal Technology (Beijing, China) and were housed at the Fourth Hospital of Hebei Medical University Experiment Animal Centre. Approximately 1 × 10⁶ HCT 116 cells suspended in 100 µl of PBS were subcutaneously injected into the right flank of each mouse. Tumor volume was measured every three days using a caliper and tumor volume was calculated by formula: tumor volume = (length × width²)/2. When the tumors’ volume reached 100 mm³, the mice were randomly divided into four groups (n = 6 per group). Control group (CON): mice were intraperitoneally injected with 0.9% physiological saline every two days. PPM group (PPM): mice were intraperitoneally injected with 3 mg/kg PPM every two days. Fluorouracil group (5-FU): mice were intraperitoneally injected with 10 mg/kg fluorouracil every two days. PPM + fluorouracil group (PPM + 5-FU): mice were intraperitoneally injected with a combination of PPM (3 mg/kg) and fluorouracil (10 mg/kg) every two days. Approximately 21 days after treatment, mice were sacrificed by spinal dislocation and the tumors were harvested and weighed. Blood were collected from eyeball and used for further analysis. The tumors were fixed in formalin and used for histological study.

Histology and Immunohistochemistry
Six mice in each group were for pathologic examinations, included hematoxylin and eosin (HE) staining and immunohistochemistry (IHC) study. Tumor tissue were fixed, dehydrated and then embedded in paraffin. Slices were cut into 4 µm and dewaxed and then dehydrated. HE staining was performed according to the protocol. Six xenografted tumors in each group were used for the quantification of the IHC studies. Immunohistochemistry (IHC) was carried out according to standard procedures. Primary antibodies of Bax (1:200, Proteintech, Wuhan, China), Bcl-2 (1:200, Proteintech, Wuhan, China), IRS1 (1:1,000, Affinity, USA), IRP1 (1:200, Affinity, USA), p-PI3K (1:200, Affinity, USA), and p-AKT (1:200, Affinity, USA) were incubated overnight at 4°C. The staining intensity was scored as follows: 0 (negative), 1 (weak staining), 2 (moderate intense staining), or 3 (strong staining). The extent of the staining was scored based on the percentage of positive cells: 0 (no staining), 1 (1–10% staining), 2 (10–50% staining), and 3 (more than 50% staining). The final IHC score was obtained by multiplying the intensity and percentage scores as described previously (13).

Blood Analysis
Routine blood test was performed by using a Mindray BC-6800Plus hematology analyzer (Mindray Biomedical Electronics, Shenzhen, China). Serum parameters of liver and kidney function were measured by Beckman Coulter AU5800 chemistry analyzer (Beckman Coulter, USA).

Statistical Analysis
Data were analyzed using GraphPad Prism v5.0 and SPSS v21.0 and are presented as means ± standard error of the mean (SEM). One-way analysis of variance (ANOVA) was used for comparisons among multiple groups and repeated measure of ANOVA was used for analysis of tumor volume. For comparisons between two groups, the SNK-q test was used. P < 0.05 was considered statistically significant.
RESULTS

PPM Inhibits the Viability of CRC Cells
To explore the effects of PPM on CRC cells, the viability of CRC cells was assessed by CCK-8 assay. The results showed that, the viability of HCT 116, RKO, HT-29, and SW480 cells were inhibited by PPM in a dose- and time-dependent manner ($P < 0.001$) (Figure 1), indicating PPM may inhibit CRC cells proliferation. The IC$_{50}$ values of PPM against HCT 116, RKO, HT-29, and SW480 cells at 24 h were 35.74 ± 8.20 ng/ml, 45.60 ± 6.30 ng/ml, 72.49 ± 5.69 ng/ml, and 112.94 ± 3.12 ng/ml, respectively. HCT 116 and RKO cell lines were more prone to the inhibition by PPM, therefore used for further analysis.

PPM Induced Cell Apoptosis in CRC Cells
To clarify the effect of PPM on the apoptosis of CRC cells, HCT 116 and RKO cells were treated with different concentration of PPM for 24 h, and the number of apoptotic cells was detected by flow cytometry. Data indicated that, compared to control, PPM treatment caused significantly increased apoptotic ratio in both HCT 116 and RKO cells in a dose dependent manner (Figure 2A). Similar results were also exhibited in TUNEL staining, which indicated that PPM treatment caused increased TUNEL-positive CRC cell ratio (Figure 2B).

Previous studies have found that the increase in the Bax/Bcl-2 ratio can lead to cytochrome c release and the subsequent cleavage and activation of caspase-3 and caspase-9, which can result in the...
This study detected these apoptosis related proteins. Data from western blot has shown that, PPM treatment caused pro-apoptotic gene expression profile, which exhibited increased pro-apoptotic gene expression such as Bax, cleaved caspase-3 and cleaved caspase-9, while decreased anti-apoptotic gene expression such as survivin and Bcl-2 (Figures 3A, B). Therefore, PPM may cause CRC cell apoptosis by targeting relative gene expression.
PPM Induced Cell Cycle Arrest

We further examined whether PPM have regulated the cell cycle. Data from flow cytometry has indicated that, compared to control, PPM treatment may cause significantly increased ratio of cells in G0/G1 phase while decreased ratio of cells in S phase, indicating PPM may promote cycle arrest in CRC cells (Figure 4A) and the maximum effect of PPM observed in the present study was at concentration of 50 ng/ml.

Cyclin D1 and p21 are both involved in cell cycle regulation. Data from the present study has found that, compared to control, PPM treatment may increase p21 expression in a dose-dependent manner in both cell lines (Figure 4B). PPM treatment led to decreased cyclin D1 gene expression at concentration of 50 ng/ml onward in HCT 116 cells, while this inhibitory effect can be found in all PPM-treated RKO cells. The maximal effect of PPM on cyclin D1 expression was noted at 100 ng/ml in both cell lines.

DEPs Identification

Tag-based (TMT) quantitative proteomics technology was performed to detect proteins of CRC cells under PPM treatment. Of those DEPs, 286 were found upregulated and 293 were downregulated. Among them, 33 of the upregulated proteins and seven of the downregulated proteins showed >2 fold-changes with \( P < 0.05 \) (Figure 5A and Table 1). The most enriched GO terms were annotated as transmembrane receptor protein tyrosine kinase activity in the molecular function category (GO: 0004714, six proteins, \( P = 8.99E^{-05} \)), low-density lipoprotein particle in the cellular compartment category (GO: 0034362, six proteins, \( P = 1.81E^{-06} \)), and animal organ morphogenesis in regard to the biological process category (GO: 0009887, 46 proteins, \( P = 1.76E^{-07} \)) (Figure 5B). KEGG pathway enrichment analysis was performed to check pathways associated with the DEPs. The results showed that 14 KEGG pathways were significantly enriched based on the number of proteins with \( P < 0.05 \). The top seven enriched pathways were Inflammatory bowel disease (five proteins, \( P = 0.001687 \)), Complement and coagulation cascades (six proteins, \( P = 0.002066 \)), Malaria (four proteins, \( P = 0.006051 \)), Pancreatic cancer (proteins, \( P = 0.010368 \)), Measles (10 proteins, \( P = 0.013437 \)), Leishmaniasis (six proteins, \( P = 0.018835 \)), and the PI3K/AKT signaling pathway (16 proteins, \( P = 0.028105 \)). DEPs were more associated with the PI3K/AKT signaling pathway which might participate in the proapoptotic effects of PPM on CRC cells (Figure 5C).

PPM Impairs PI3K/AKT Signaling Pathway

PI3K/AKT signaling pathway activation has been found promotes tumor progression and cell survival by inhibition of apoptosis (15). PI3K and AKT are both the downstream target genes of IRS1 (16) and the phosphorylation forms are the active ones. In the present study, consistent with TMT-based results, PPM treatment caused significantly decreased IRS1 expression in HCT and RKO cells compared to control cells in almost a PPM concentration-dependent manner. Although gene expression of PI3K and AKT were not altered, both p-PI3K and p-AKT were significantly decreased by PPM treatment. Therefore, PPM treatment may impair PI3K/AKT signaling pathway, contributing to increased CRC cell apoptosis ratio (Figures 6A, B). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the iProX partner repository \( PXD029172 \).

The Effects of PPM on Blood Parameters

To examine the safety of PPM, blood parameters were checked in the nude mice. Data indicated that, compared to CON animals,
PPM treatment caused no alterations in blood cells, hepatic and renal functional parameters. However, 5-FU treated animals exhibited lower WBC number and higher ALT and AST levels compared to CON animals ($P < 0.05$), indicating hypoleukemia and liver functional impairment. Only increased UN level was found in PPM + 5-FU group, indicating that 5-FU combined with PPM might cause renal functional impairment. Meanwhile, the WBC count and ALT, AST levels in PPM + 5-FU group showed no difference compared to those in CON group, suggesting PPM might alleviate the adverse effects of 5-FU on hepatic function and WBC (Table 2).

The Effects of PPM on Colorectal Tumor Formation In Vivo

To explore the effects of PPM on CRC cells in vivo, BALB/c nude mice with HCT 116 cells xenografted tumor were treated. Data from the present experiment has shown that, compared to control animals, PPM, 5-FU and PPM + 5-FU treatment all could impair tumor growth. There were no statistical differences in tumor volume between 5-FU and PPM-treated group (Figures 7A, B). At day 21, compared to control group, the weights of tumors were found reduced in PPM, 5-FU and PPM + 5-FU treated animals. There were no statistical differences in tumor weight between 5-FU and PPM-treated group (Figure 7C). The tumor weight in PPM + 5-FU-treated group was even lower when compared to PPM and 5-FU-treated groups separately (Figure 7C), indicating the anti-tumor effect might be exaggerated in PPM and 5-FU combination treatment.

Gene expression involved in cell apoptosis were also measured by immunohistochemistry, which indicated that PPM, 5-FU, and PPM + 5-FU treatment all led to increased gene expression of Bax and cleaved caspase-3 while decreased expression of IRS1, p-PI3K, and p-AKT (Figure 7D), indicating PPM may perform pro-apoptotic effects in vivo. Except p-PI3K, the most manifest effects in those gene expressions were found in PPM + 5-FU-treated animals, suggesting the pro-apoptotic effects might also be exaggerated by PPM and 5-FU combination therapy strategy.
DISCUSSION

Colorectal cancer (CRC) is one of the most common malignancies worldwide, and is the second leading cause of tumor death (18). For some stage IV colon and rectal cancers with metastases, radiotherapy and chemotherapy therapy are the main therapy strategies so far. However, the chemotherapy drugs are effective but combined with unwanted toxicity and side effects (5).

It has been found that, cardiac glycosides (CG) may have the ability to induce tumor cell death in vitro (19–21). Retrospective
clinical analyses revealed that, CG digoxin administration during chemotherapy may improve overall survival in cohorts of breast, colorectal, head and neck, and hepatocellular carcinoma patients (22). Moreover, elevated plasma digitoxin levels have been found previously correlate with reduced incidence of leukemia, lymphoma, and kidney/urinary tract tumors in patients (23).

PPM, a cardiac glycoside isolated from *Cortex Periplocae*, has been used for chronic congestive heart failure treatment due to its effect of strengthen myocardial contractility (24). Previous studies performed in some tumor cells, such as PC3, U937, MCF-7, and SMMC-7721, have found that, PPM has potent anti-cancer effect by inhibiting cells growth and promoting apoptosis (10, 12), suggesting PPM applications in anti-cancer treatment.

Most anti-cancer therapies trigger apoptosis to eliminate malignant cells (25, 26). Previous study indicated that PPM inhibited prostate cancer cell line PC3 growth by the activation of caspase-dependent apoptotic pathways (10). PPM also could sensitize U937 cells to TNF-related apoptosis, which was more quickly than the ouabain (10). In the present experiment, we have found that PPM promoted CRC cell apoptosis in *vitro*. Our study showed PPM treatment led to a significant reduction in the viability of several CRC cell lines and increased the rate of apoptosis in HCT 116 and RKO cells in a dose-dependent manner. In addition, we are first to discover that PPM could trigger an increase of expression profile for the pro-apoptotic proteins Bax, cleaved caspase-3, and cleaved caspase-9, and a decrease in those of the anti-apoptotic proteins Bcl-2 and survivin, contributing to increased apoptotic ratio in CRC cell (14, 27). However, mechanisms underlying PPM modulating apoptosis is still quite limited and detailed studies needs to be further performed.

Cell cycle disruption has been found in pathogenesis of tumors (28). In this study, we observed that PPM treatment could cause significantly increased ratio of cells in G0/G1 phase

### TABLE 1 | DEPs between PPM-treated groups and control groups in HCT 116 cells.

| Accession | Protein Name | Gene Name | Fold chang | p value |
|-----------|--------------|-----------|------------|---------|
| Up-regulated proteins | | | | |
| Q8NL4L8 | Coiled-coil domain-containing protein 24 | CCDC24 | 6.81 | 0.04 |
| Q9GZ2R1 | Serine-specific protease 6 | SENS6 | 4.71 | 0.02 |
| Q3V5T2 | Girdin | CDK8 | 4.63 | 0.03 |
| P9R1T7 | FYVE, RhoGEF and PD domain-containing protein 1 | FOD1 | 4.44 | 0.04 |
| Q9H5B1 | Zinc finger protein 385D | ZNF385D | 3.86 | 0.01 |
| Q9Y227 | Ectonucleoside triphosphate diphosphohydrolase 4 | ENTPT4 | 3.35 | 0.02 |
| Q8N511 | Transmembrane protein 199 | TMEM199 | 3.30 | 0.04 |
| P0S060 | Secretogranin-1 | CHGB | 3.29 | 0.01 |
| Q9H2S1 | Small conductance calcium-activated potassium channel protein 2 | KCNN2 | 3.20 | 0.00 |
| Q5T4E8 | Protein THEMIS2 | THEMIS2 | 3.19 | 0.02 |
| Q30167 | HLA class II histocompatibility antigen, DRB1-10 beta chain | HLA-DRB1 | 3.07 | 0.04 |
| A0A1B0GUA6 | Putative coiled-coil domain-containing protein 195 | CCDC195 | 3.08 | 0.01 |
| Q96QD8 | Sodium-coupled neutral amino acid transporter 2 | SLC38A2 | 3.00 | 0.00 |
| Q02410 | Amyloid-beta A4 precursor protein-binding family A member 1 | APBA1 | 2.97 | 0.03 |
| Q9NN2 | Oferta30m-like protein 3 | OFZM3 | 2.73 | 0.02 |
| A9TX70 | Collagen alpha-2(VI) chain | COLA2V | 2.69 | 0.01 |
| Q9NF09 | Dual oxidase 1 | DUOX1 | 2.52 | 0.00 |
| Q8NWSV | PCNA-interacting partner | PARPB | 2.51 | 0.02 |
| Q8SEX45 | Protein tIB homolog | LRPC6 | 2.50 | 0.04 |
| Q7KAK9 | Rho GTPase-activating protein 32 | ARHGAP32 | 2.33 | 0.01 |
| Q5SHC0 | Coiled-coil domain-containing protein 92 | CCDC92 | 2.29 | 0.02 |
| Q9JBU7 | Protein DBF4 homolog A | DBF4 | 2.26 | 0.03 |
| Q8V2A0 | RESt corepressor 2 | RCR2 | 2.25 | 0.00 |
| Q8WV79 | Solute carrier family 13 member 3 | SLC13A3 | 2.24 | 0.03 |
| Q8FAE9 | Protein spire homolog 1 | SPIRE1 | 2.19 | 0.01 |
| Q9HHO4 | Zinc finger protein 408 | ZNF408 | 2.15 | 0.00 |
| Q9UH2H | Dynin heavy chain 17, axonemal | DNAM17 | 2.13 | 0.04 |
| Q16515 | Acid-sensing ion channel 2 | ASIC2 | 2.12 | 0.00 |
| Q8TE73 | Dynin heavy chain 5, axonemal | DNAH5 | 2.12 | 0.00 |
| Q75037 | Kinesin-like protein KIF21B | KIF21B | 2.10 | 0.02 |
| Q14934 | Nuclear factor of activated T-cells, cytoplasmic 4 | NFTAC4 | 2.06 | 0.01 |
| Q5V667 | Peroxisome proliferator-activated receptor gamma coactivator-related protein 1 | PPARC1 | 2.02 | 0.00 |
| Q9BZ88 | Natural killer cell receptor 2B4 | CD244 | 2.02 | 0.01 |
| Down-regulated proteins | | | | |
| O00767 | Acyl-CoA desaturase | SCD | 0.49 | 0.00 |
| P05373 | Metallothionein-1F | MT1F | 0.47 | 0.01 |
| P09669 | Cytochrome c oxidase subunit 6C | COX6C | 0.45 | 0.04 |
| P62987 | Ubiquitin-60S ribosomal protein L40 | UBA52 | 0.45 | 0.01 |
| P15153 | Ras-related C3 botulinum toxin substrate 2 | RAC2 | 0.45 | 0.04 |
| Q9ULR5 | Polyadenylate-binding protein-interacting protein 2B | PAIP2B | 0.41 | 0.04 |
| P63722 | Transcription elongation factor SPT4 | SUPT4H1 | 0.41 | 0.04 |
while decreased ratio of cells in S phase, indicating PPM promoted cycle arrest in CRC cells. But the maximum effect of PPM observed was at concentration of 50 ng/ml, suggesting that its effect on cell cycle does not enhance as the drug concentration increases when greater than 50 ng/ml. Protein p21 is a negative regulator of G1/S transition (29), and downregulation of p21 is involved in tumor promotion in various cancers (30, 31). Oncogene cyclin D1 has been found overexpressed in human cancers (32) and implicated in many activities, such as cell cycle promotion, chromosomal instability, mitochondrial function and cellular senescence (33). Previous studies have found that cyclin D1 binds and sequesters p21, thereby allowing the progression from G1 to S phase (34). In the present study, we found that PPM treatment increased p21 and decreased cyclin D1 gene expression, indicating that PPM reduced CRC cell proliferation mainly by causing cell cycle arrests, and this effect might be achieved by increasing p21 and reducing cyclin D1 expression. Similar results have also been found in some other traditional Chinese medicine, such as curcumol and pigallocatechin-3-gallate (35, 36). But the maximal effect of PPM on p21 and cyclin D1 expression was noted at 100 ng/ml, indicating that there might be other proteins involved in the cell cycle regulation of PPM treatment, which needs further research.

Quantitative proteomic techniques have been widely applied due to their ability to reveal the dynamics of protein expression and protein-protein interactions from a global perspective, which greatly help to understand the gene function in cellular processes (37). In this study, the proteomic approach has been introduced to identify PPM treatment-associated DEPs. A total of 6,645 proteins were identified, of these, 539 were found to be differentially expressed. Gene Ontology (GO) analysis suggests these proteins have important functions in various metabolic processes, (e.g., transmembrane receptor protein tyrosine kinase activity, signaling receptor activity, and molecular transducer activity). PI3K/AKT signaling pathway was selected for further mechanism research owing to its high enrichment factor and more DEPs associated according to the KEGG analysis. At the same time, the results also showed that IRS1, as the upstream of PI3K, was down-regulated after PPM treatment.

PI3K/AKT signaling pathway plays an important role in tumor cell growth, proliferation and survival by regulating apoptosis-related genes (15). Elevated level of phosphorylated PI3K and

![FIGURE 6](Image)

Periplocymarin (PPM) modulates gene expression involved in PI3K/AKT signaling pathway. PPM treatment altered the expression levels of IRS1, PI3K, AKT, p-PI3K, and p-AKT in HCT 116 (A) and RKO cells (B). Values are shown as means ± SEM. *P < 0.05, **P < 0.01, vs. untreated control group.

| TABLE 2 | The effects of periplocymarin (PPM) and 5-FU on blood cell counts and liver and kidney function. |
|---|---|---|---|---|---|---|---|
| | WBC (×10^9/L) | RBC (×10^{12}/L) | PLT (×10^9/L) | ALT (U/L) | AST (U/L) | CREA (μmol/L) | UN (mmol/L) |
| CON | 0.64 ± 0.06 | 3.33 ± 0.04 | 309.67 ± 11.57 | 10.63 ± 1.20 | 57.40 ± 10.06 | 2.27 ± 0.46 | 2.47 ± 0.09 |
| 5-FU | 0.32 ± 0.04* | 3.37 ± 0.11 | 276.00 ± 26.01 | 47.53 ± 13.43* | 113.67 ± 20.07* | 4.67 ± 0.44 | 6.77 ± 1.26 |
| PPM | 0.68 ± 0.06 | 3.42 ± 0.01 | 327.33 ± 16.76 | 8.00 ± 1.66 | 37.03 ± 0.58 | 2.33 ± 0.18 | 2.20 ± 0.17 |
| PPM + 5-FU | 0.54 ± 0.08 | 3.51 ± 0.09 | 336.00 ± 7.21 | 25.13 ± 4.0 | 77.03 ± 4.71 | 3.93 ± 1.66 | 5.23 ± 0.27* |

WBC, white blood cell; RBC, red blood cell; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CREA, creatinine; UN, urea nitrogen. Data were present as mean±SEM. N=3 per/group. *P < 0.05 vs. CON group.
AKT were found in human CRC samples, which was correlated with a poor disease outcome (38). Activated PI3K/AKT signaling pathway has been suggested favorable for cells survival through inhibiting apoptosis and impair cell cycle arrest by targeting downstream genes, including Bcl-2 family, caspase family, survivin, p21, and cyclin D (39–43). Inhibition of PI3K/AKT signaling pathway has been found effective in inhibition of tumor cells of different tissues (44–46). IRS1, upstream of PI3K and major substrate of insulin, insulin-like growth factors and cytokine signaling, plays an important role in mediating apoptosis, cell differentiation, and cell transformation (47). IRS1 is constitutively activated in a variety of solid tumors, namely, CRC, breast cancers, leiomyomas, Wilms tumors, rhabdomyosarcomas, liposarcomas, leiomyosarcomas, and adrenal cortical carcinomas (48). In the present study, we found that PPM reduced IRS1, p-PI3K, and p-AKT gene expression and caused impaired PI3K/AKT signaling pathway in CRC cells, which might lead to increased apoptotic ratio and promoted cell cycle arrest.

Also, in the present experiment, we have checked the effect and safety of PPM in animal models. We have found that, PPM performed comparable anti-tumor effect with 5-FU, but with less negative effects in white cells and liver function. Studies about PPM on blood, renal and hepatic function is little. It has been found that the toxicity of Cortex Periplocae is mainly cardiac glycoside poisoning (49). However, previous study has found that, Cortex Periplocae extract may reverse the white blood cell decline caused by cyclophosphamide (50). Wan et al. (51) found that periplocoside A, another nature product compound isolated from Cortex Periplocae, may prevent liver damage caused by concanavaline A. Intriguingly, the PPM + 5-FU combination therapy strategy seemed more effective in tumor suppression than single drug treatment, and only slightly renal function impairment was observed, indicating PPM might be added to other traditional anti-tumor therapy, more favorable effects would be achieved with less side effects. However, long-term in vivo effect of PPM still needs to be investigated. In addition, the cardiovascular safety of PPM is still needed to be warranted.

In conclusion, data from this experiment indicated that PPM performed anti-tumor effects both in vivo and in vitro. Inhibited PI3K/AKT signaling pathway might be involved in this process. A diagram for the mechanism of PPM-induced apoptosis and cell

FIGURE 7 | The effect of periplocymarin (PPM) on colorectal cancer cells in nude mice. (A) Images of tumors derived from mice in each group. (B) Tumor volumes were calculated in each group every 3 days from days 1 to 21. (C) Tumor weights were measured on day 21. (D) Hematoxylin/eosin-stained sections of tumor tissues derived from mice in each treatment group were presented. Magnification: 200x. Scale bar, 150 µm. The expression of Bax, cleaved caspase-3, IRS1, p-PI3K, and p-AKT in tumor tissues of mice from each treatment group was examined by immunohistochemistry. Magnification: 400x. Scale bar, 70 µm. *P < 0.05, **P < 0.01, vs. untreated control group. †P < 0.05, vs. 5-FU treatment group. ‡P < 0.05, vs. PPM treatment group. n = 6 per group.
cycle arrest via impairing PI3K/AKT signaling pathway in CRC cells is shown in Figure 8. PPM is a promising chemotherapeutic drug for CRC treatment but extended safety evaluation should be performed.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The animal study was reviewed and approved by the Experimental animal ethics committee of the Fourth Hospital of Hebei Medical University.

AUTHOR CONTRIBUTIONS

GW and LZ conceived the study. YC, SD, and CZ performed the experiment. JH and XH analyzed experimental results. HM, BL, and ZM provided advice on the study design and data interpretation. YC and FW wrote the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Natural Science Foundation of China (Grant No. 81772550), Natural Science Foundation precision medicine joint project of Hebei Province, China.
REFERENCES

1. Sung H, Ferlay J, Siegel RL, Soerjomataram I, Laversanne M, Jemal A. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71:219–49. doi: 10.3322/caac.21660

2. Garborg K, Holme O, Leberg M, Kalager M, Adami HO, M. Brehm. Current Status of Screening for Colorectal Cancer. Ann Oncol (2013) 24:1963–72. doi: 10.1093/annonc/mdt1157

3. Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JY, Young GP, et al. Colorectal Cancer Screening: A Global Overview of Existing Programmes. Gut (2015) 64:1637–49. doi: 10.1136/gutjnl-2014-309086

4. Zeng H, Chen W, Zheng R, Zhang S, Li J, Zhou S, et al. Changing Cancer Survival in China During 2003-15: A Pooled Analysis of 17 Population-Based Cancer Registries. Lancet Glob Health (2018) 6:e555–67. doi: 10.1016/s2214-109x(18)30127-x

5. Shibahara K, Tomonaga M, Banerjee P, Richa H, Benetkiewicz M, André T, et al. Therapeutic Strategy in Unexpected Metastatic Colorectal Cancer: An Updated Review. Ther Adv Med Oncol (2015) 7:153–69. doi: 10.1177/1758834015572343

6. Newman DJ, Cragg GM. Natural Products as Sources of New Drugs From Potential Natural Compound for Drug Development: Highly Permeable With Enzymatic Stability and Specificity. J Nat Prod (2020) 83. doi: 10.1021/acs.jnatprod.5b01055

7. C. P. Commission. Chinese Pharmacopoeia. 2015 edition Vol. First volume. Beijing: China Medical Science and Technology Press (2015) p. 257–8.

8. Zhang HY, Xu WQ, Zheng YY, Omari-Siaw E, Zhu Y, Cao X, et al. Octreotide-Periplocyramin Conjugate Prodrug for Improving Targetability and Anti-Tumor Efficiency. Synthesis, In Vitro and In Vivo Evaluation. Oncotarget (2016) 7:86326–38. doi: 10.18632/oncotarget.13389

9. Zhang H, Xu W, Omari-Siaw E, Liu Y, Chen B, Chen D, et al. Redox-Responsive PEgalted Self-Assembled Prodrug-Nanoparticles Formed by Single Disulfide Bond Bridge Periplocyramin-Vitamin E Conjugate for Liver Cancer Chemothrapy. Drug Delivery (2017) 24:1170–8. doi: 10.1080/10717544.2017.1365393

10. Bloise E, Braca A, De Tommasi N, Belisario MA. Pro-Apoptotic and Cytostatic Activity of Naturally Occurring Cardenolides. Cancer Chemother Pharmacol (2009) 64:793–802. doi: 10.1007/s00280-009-0929-5

11. Li M-y, Yang X, Yan C-y, Xiao Z-j, Jiang W-q, Wang X-y, et al. Research on Chemical Composition and Pharmacological Effects of Periplocarpae Cortex and Predictive Analysis on Q-Marker. Chin J Chin Mater Med Pharmacol (2020) 45:2772–83. doi: 10.19540/j.cnki.cjcmm.20200327.202

12. Martey ON, He X, Xing H, Deng F, Feng S, Li C, et al. Periplocyramin is a Potential Natural Compound for Drug Development: Highly Permeable With Absence of P-Glycoprotein Efflux and Cytochrome P450 Inhibitions. Biopharm Drug Disp (2014) 35:195–206. doi: 10.1002/bdd.1884

13. Gu J, Huang W, Zhang J, Wang X, Tao T, Yang L, et al. TmPRSS4 Promotes Cell Proliferation and Inhibits Apoptosis in Pancreatic Ductal Adenocarcinoma by Activating ERK1/2 Signaling Pathway. Front Oncol (2021) 11:628533. doi: 10.3389/fonc.2021.628533

14. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of Apoptosis by the BCL-2 Protein Family: Implications for Physiology and Therapy. Nat Rev Mol Cell Biol (2014) 15:49–63. doi: 10.1038/nrm3722

15. Jiang N, Dai Q, Su X, Fu J, Feng X, Peng J. Role of PI3K/AKT Pathway in Cancer: The Framework of Malignant Behavior. Mol Biol Rep (2020) 47:4587–629. doi: 10.1007/s11033-020-05435-1

16. Haeseler RA, McGraw TE, Accili D. Biochemical and Cellular Properties of Insulin Receptor Signalling. Nat Rev Mol Cell Biol (2018) 19:31–44. doi: 10.1038/nrm.2017.89

17. Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. Iprox: An Integrated Proteome Resource. Nucleic Acids Res (2019) 47:D12121–D1217. doi: 10.1093/nar/gky869

18. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68:394–424. doi: 10.3322/caac.21492

ACKNOWLEDGMENTS

Thanks for the contributions of teachers from the Scientific Research Center of the Fourth Hospital of Hebei Medical University.
38. Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M. Phosphorylation of Akt/ PKB is Required for Suppression of Cancer Cell Apoptosis and Tumor Progression in Human Colorectal Carcinoma. Cancer (2002) 94:3127–34. doi: 10.1002/cncr.10591
39. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Ballock WL, et al. Involvement of PI3K/Akt Pathway in Cell Cycle Progression, Apoptosis, and Neoplastic Transformation: A Target for Cancer Chemotherapy. Leukemia (2003) 17:590–603. doi: 10.1038/sj.leu.2402824
40. Tewari D, Patni P, Bishayee A, Sah AN, Bishayee A. Natural Products Targeting the PI3K-Akt-mTOR Signaling Pathway in Cancer: A Novel Therapeutic Strategy. Semin Cancer Biol (2019), S1044–579X(19)30405-5. doi: 10.1016/j.semcancer.2019.12.008
41. Bahrami A, Khazaei M, Hasanzadeh M, ShahidSales S, Joudi Mashhad M, Farazestanian M, et al. Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress. J Cell Biochem (2018) 119:2460–9. doi: 10.1002/jcb.25950
42. Stiles BL. PI-3-K and AKT: Onto the Mitochondria. Adv Drug Delivery Rev (2009) 61:1276–82. doi: 10.1016/j.addr.2009.07.017
43. Wheatley SP, Altieri DC. Survivin at a Glance. J Cell Sci (2019) 132:223826–34. doi: 10.1242/jcs.223826
44. Huang Z, Liu CA, Cai PZ, Xu FP, Zhu WJ, Wang WW, et al. Omega-3pufa Attenuates MNU-Induced Colorectal Cancer in Rats by Blocking PI3K/AKT/Bcl-2 Signaling. Onco Targets Ther (2020) 13:1953–65. doi: 10.2147/ott.S241298
45. Sui Y, Zheng X, Zhao. Rab31 Promoted Hepatocellular Carcinoma (HCC) Progression via Inhibition of Cell Apoptosis Induced by PI3K/AKT/Bcl-2/BAX Pathway. Tumour Biol (2015) 36:3661–70. doi: 10.1007/s13277-015-3626-5
46. Surmeli Z, Gursoy P, Erdogan AP, Bozkurt E, Atmaca H, Uzunoglu S, et al. Combination of Zoledronic Acid and Serine/Threonine Phosphatase Inhibitors Induces Synergistic Cytotoxicity and Apoptosis in Human Breast Cancer Cells via Inhibition of PI3K/Akt Pathway. Tumour Biol (2016) 37:3665–73. doi: 10.1007/s13277-015-3265-x
47. White MF. IRS Proteins and the Common Path to Diabetes. Am J Physiol Endocrinol Metab (2002) 283:E413–22. doi: 10.1152/ajpendo.00514.2001
48. Chang Q, Li Y, White MF, Fletcher JA, Xiao S. Constitutive Activation of Insulin Receptor Substrate 1 is a Frequent Event in Human Tumors: Therapeutic Implications. Cancer Res (2002) 62:6035–8.
49. Li Y, Li J, Zhou K, He J, Cao J, An M, et al. A Review on Phytochemistry and Pharmacology of Cortex Periplocae. Molecules (2016) 21:1702. doi: 10.3390/molecules21121702
50. Xu Shuo JP, Xu W, Wu X, Jiang W, Kuang Y, Ma J. Advances on Chinese Herbal Medicine Periplocae Cortex. Northwest Pharm J (2017) 32:118–21. doi: 10.3969/j.issn.1004-2407.2107.01.032
51. Wan J, Zhu YN, Feng QJ, Chen HJ, Zhang RJ, Ni J, et al. Periplocoside A, a Pregnan Glycoside From Periploca Sepium Bge, Prevents Concanavalin A-Induced Mice Hepatitis Through Inhibiting NKT-Derived Inflammatory Cytokine Productions. Int Immunopharmacol (2008) 8:1248–56. doi: 10.1016/j.intimp.2008.05.001

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Cheng, Wang, Zhao, Dai, Han, Hu, Zhou, Wang, Ma, Li and Meng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.